Core Viewpoint - The biomanufacturing sector is recognized as a key engine for the new technological revolution and industrial transformation, with Changde aiming to establish itself as a national-level industrial cluster by 2025 [1][4]. Group 1: Industry Development - Changde has nurtured several biopharmaceutical companies, including YunGang Bio and LiEr Bio, with 35 core enterprises in synthetic biomanufacturing expected to achieve a production value exceeding 7.5 billion yuan by mid-2025 [1][4]. - YunGang Bio has developed a GMP-standard automated production line for extracting and synthesizing ursodeoxycholic acid from animal bile, achieving a conversion rate of over 99% and capturing more than one-third of the domestic market for its core product [2][3]. - Changde's synthetic biomanufacturing industry has shown significant growth, with a production value of 7.689 billion yuan as of July 2025, reflecting a year-on-year increase of 23.52% [3]. Group 2: Technological Innovation - The foundation of synthetic biology and biomanufacturing is held by companies like MuEn Bio, which has identified over 320,000 proprietary microbial strains, enabling high-throughput screening for bioactive microorganisms and their metabolites [2][3]. - MuEn Bio has established a comprehensive DREAM technology platform that covers the entire process from resource discovery to product development, enhancing its competitive edge in biomanufacturing [3]. Group 3: Ecosystem and Support - Changde is building a comprehensive industrial ecosystem with support from policies, talent acquisition, and financial backing, aiming to accelerate the transition from technological breakthroughs to large-scale implementation [4][5]. - The establishment of a 5 billion yuan biomanufacturing mother fund and a 1 billion yuan innovation guidance fund is part of Changde's strategy to inject "patient capital" into the biomanufacturing sector [4]. Group 4: Future Prospects - By 2028, Changde aims to achieve a production value of over 30 billion yuan in synthetic biomanufacturing and to cultivate more than 100 enterprises in the sector, including over 50 high-tech companies [6]. - The biomanufacturing industry in China has reached a total scale of nearly 1 trillion yuan, with fermentation capacity accounting for over 70% of the global market, indicating significant growth potential [5][6].

建设内容：在本公司"微元合成绿色生物制造二期项目"车间内，建设"微元合成绿色生物制造二期健 康糖项目"，利用现有发酵、公用工程和检验等设备，新增膜分离、离交、浓缩、结晶、分离干燥等 设备， 项目建成后， 柔性生产阿洛酮糖和甘露糖醇（食品级）， 年产量共计2000吨 。 阿洛酮糖 作为一种新型低倍甜味剂，具备多种生理功效，如抑制人体对糖类的吸收、降血糖、抗氧 化等，是蔗糖的理想替代品。 甘露糖醇 则广泛应用于医药、食品、化工等领域，作为甜味剂、保湿 剂、赋形剂等。 2、在建项目 "微元合成绿色生物制造二期项目"，项目运用生物提取技术，以一水合葡萄糖、柠檬酸、磷酸二氢 钾、硫酸钾等组分组成的培养液为基本原料，利用菌体进行发酵得到产物胆红素后进行纯化提取，从 而制出胆红素产品。目前项目正在建设过程中，建成后年生产胆红素5吨。 3、微元合成 【SynBioCon】 获悉，近日，关于 微元合成生物技术（秦皇岛）有限公司 微元合成绿色生物制造 二期健康糖项目在相关网站批复前公示。 1、项目基本情况 项目名称：微元合成绿色生物制造二期健康糖项目 建设单位：微元合成生物技术（秦皇岛）有限公司 项目投资：4000万元 微元合成 ...